CIRM Funded Clinical Trials

A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors


Dennis Slamon
Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$6,924,317
Trial Sponsor:
University Health Network, Toronto
Trial Stage: 
Phase 1
Trial Status: 
Recruiting
Targeted Enrollment:
48
ClinicalTrials.gov ID:
Details: 

Solid tumors are the most prevalent form of cancer, and are a major cause of death worldwide.  The small molecule being developed inhibits the activity of a protein required in tumor cell lines and cancer stem cells (CSC). It is hypothesized that inhibiting the CSC can prevent tumor regrowth after treatment. 

Design: 

Dose escalation and expansion.

Goal: 

Determination of maximum tolerated dose and recommended Phase 2 dose. Safety. PK. Efficacy in solid cancers.

Status: 

Ongoing.